| 436.5354 2.925 (0.67%) | 10-15 12:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 536.67 | 1-year : | 626.83 |
| Resists | First : | 459.48 | Second : | 536.67 |
| Pivot price | 439.58  |
|||
| Supports | First : | 419.63 | Second : | 395 |
| MAs | MA(5) : | 439.7  |
MA(20) : | 435.44 |
| MA(100) : | 339.44 |
MA(250) : | 340.4 |
|
| MACD | MACD : | 16.4 |
Signal : | 20.6 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 55.7 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 459.48 | Low : | 266.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UTHR ] has closed above bottom band by 49.7%. Bollinger Bands are 19% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 442.51 - 444.96 | 444.96 - 446.95 |
| Low: | 423.2 - 426.68 | 426.68 - 429.5 |
| Close: | 428.49 - 433.65 | 433.65 - 437.85 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Mon, 13 Oct 2025
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting - FinancialContent
Mon, 13 Oct 2025
United Therapeutics Corporation (UTHR) Stock Analysis: Unpacking a Promising 12% Upside Potential - DirectorsTalk Interviews
Sun, 12 Oct 2025
Prime Capital Investment Advisors LLC Reduces Stake in United Therapeutics Corporation $UTHR - MarketBeat
Sat, 11 Oct 2025
A Fresh Look at United Therapeutics (UTHR) Valuation Following Recent Share Price Momentum - simplywall.st
Sat, 11 Oct 2025
A Fresh Look at United Therapeutics (UTHR) Valuation Following Recent Share Price Momentum - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 99.2 (%) |
| Shares Short | 2,190 (K) |
| Shares Short P.Month | 2,700 (K) |
| EPS | 25.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 158.64 |
| Profit Margin | 40.3 % |
| Operating Margin | 45.6 % |
| Return on Assets (ttm) | 12.9 % |
| Return on Equity (ttm) | 19.2 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 60.57 |
| Sales Per Share | 68.09 |
| EBITDA (p.s.) | 35.37 |
| Qtrly Earnings Growth | 9.6 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 811 (M) |
| PE Ratio | 17.13 |
| PEG Ratio | 0 |
| Price to Book value | 2.76 |
| Price to Sales | 6.45 |
| Price to Cash Flow | 14.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|